Subsequent Events |
9 Months Ended | ||||||
---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||
Subsequent Events [Abstract] | |||||||
Subsequent Events |
11. Subsequent Events Initial Public Offering On September 26, 2018, the Company’s registration statement on Form S-1 (File Nos. 333-227103 and 333-227548) relating to its IPO of its common stock was declared effective by the SEC and the shares of its common stock began trading on the Nasdaq Global Market on September 27, 2018. The public offering price of the shares sold in the IPO was $15.00 per share. The IPO closed on October 1, 2018, pursuant to which the Company sold 5,667,000 shares of common stock, for gross proceeds of approximately $85.0 million. The Company received net proceeds from the IPO of approximately $74.4 million, after underwriting discounts, commissions and estimated offering expenses. In addition to the shares of common stock sold in the IPO, the Company concurrently sold in a private placement to Merck, 666,666 shares of common stock at the IPO offering price of $15.00 per share, for proceeds of approximately $10.0 million.
|